| Abstract: | Dear Editor,
Myocardial infarction(MI)is the irreversible cardiomyocyte death resulting from prolonged oxygen deprivation due to obstructed blood supply(ischemia),leading to contractile dysfunction and cardiac remodeling.In recent decades,stem cell transplantation has been extensively investigated for the repair of injured heart in animal studies and clinical trials(Kanelidis et al.,2017;Gyongyosi et al.,2018).Among cell-based therapies in clinical development,mesenchymal progenitor cells(MPCs)are attractive candidates due to their multi-lineage potential and immunomodulatory properties(Bagno et al.,2018).However,low quality(e.g.,reduced proliferative ability and increased cellular senescence at late passages)and heterogeneous cell sources,as well as poor retention and survival rate of transplanted MPCs in an in vivo niche present obstacles towards broader clinical applications(Nguyen et al.,2016;Li et al.,2020). |
